Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac
With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.<
CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k
Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan
Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs
In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.